The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Carl Borrebaeck

Carl Borrebaeck

Professor

Carl Borrebaeck

Antibody microarray-based oncoproteomics

Author

  • Carl Borrebaeck

Summary, in English

The driving force behind oncoproteomics is the belief that certain protein signatures or patterns exist that are associated with a particular malignancy. if so, the correlation of clinical parameters with defined protein expression patterns would allow us to predict disease progression and perhaps even postulate improved therapeutic modalities. The technological challenges to achieve these goals are significant, as the human proteome is not defined. No general methodological approach exists today, and human cancer can, furthermore, be divided into several disease subgroups. One potential solution to finding cancer-associated protein signatures is the emerging technology of affinity proteomics. This approach addresses some of the shortcomings of traditional proteomics and combines it with the power of microarrays. The present review focuses on the role of antibody microarrays in oncoproteomics and its potential to provide a truly proteome-wide analytical approach.

Department/s

  • Department of Immunotechnology

Publishing year

2006

Language

English

Pages

833-838

Publication/Series

Expert Opinion on Biological Therapy

Volume

6

Issue

8

Document type

Journal article

Publisher

Ashley Publications

Topic

  • Immunology in the medical area

Keywords

  • recombinant
  • antibody
  • proteome analysis
  • microarray
  • affinity proteomics
  • cancer

Status

Published

ISBN/ISSN/Other

  • ISSN: 1471-2598